- Poster presentation
- Open Access
Pioglitazone alters fat distribution in patients with type 2 diabetes mellitus, in contrast to metformin
© Jonker et al; licensee BioMed Central Ltd. 2009
- Published: 28 January 2009
- Glycemic Control
- Increase Body Weight
- Pioglitazone Group
Diabetes mellitus is associated with an increased risk on cardiovascular disease and epicardial fat has been proposed as an additional cardiovascular risk factor. Treatment with pioglitazone leads to an improvement in glycemic control, but also increases body weight.
The primary aim was to evaluate the effect of pioglitazone on weight and fat distribution in patients with type 2 diabetes mellitus (DM2). The secondary aim was to assess the relationship of epicardial fat to anthropometric measurements and fat distribution in these patients
Seventy-seven male patients with DM2 were included in this study (mean ± SEM, age 56.5 ± 0.6 yr; HbA1c 7.1 ± 0.1%), without cardiac ischemia. Patients were randomly assigned to pioglitazone (30 mg/day) or metformin (2000 mg/day) and matching placebo during 24 weeks. Epicardial fat and abdominal visceral and subcutaneous fat were measured by magnetic resonance imaging. Myocardial and hepatic triglyceride content (TG) were determined by 1H magnetic resonance spectroscopy.
In patients with DM2 there is a relation between epicardial fat mass, BMI and visceral fat mass. Pioglitazone increases body weight, epicardial fat and subcutaneous fat mass in patients with DM2 treated with pioglitazone, whereas hepatic triglyceride content decreases.
This article is published under license to BioMed Central Ltd.